Douglas A. Levine, MD

Douglas A. Levine, MD

Director, Gynecologic Oncology
Head, Gynecology Research Laboratory
Professor, Division of Gynecologic Oncology
Laura and Isaac Perlmutter Cancer Center
New York University Langone Health

Douglas Levine MD is gynecologic oncologist who specializes in the surgical treatment of women with known or suspected ovarian or uterine cancers.

In addition to caring for patients, Dr. Levine heads the Gynecology Research Laboratory, where his efforts focus on the genomics of ovarian and endometrial cancers. Specifically, Dr. Levine is trying to identify clinically relevant genomic predictors of outcome for women with ovarian or endometrial cancer. A major portion of his research also focuses on studying molecular profiles of women who are treated with novel targeted anticancer drugs. His goal is to determine which patients are most likely to respond to a given therapy so that we can direct the best treatments toward the most appropriate patients. Dr. Levine uses whole-genome techniques and other methods to molecularly characterize ovarian and uterine cancers from patients treated at NYU’s Perlmutter Cancer Center and on national cooperative group clinical trials. Dr. Levine’s research has been supported by funding from the National Cancer Institute, the Department of Defense, Stand Up To Cancer, Ovarian Cancer Research Alliance, the Gynecologic Cancer Foundation, and the Entertainment Industry Foundation.

Dr. Levine also has an active interest in medical education and innovative technology. He has authored or co-authored more than 200 peer-reviewed research papers, review articles, and book chapters. Dr. Levine has been very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He serves as co-chair of the ovarian, endometrial, and uterine carcinosarcoma disease working groups. He is a member of the Scientific Advisory Committee of the Ovarian Cancer Research Fund, the Clearity Foundation, and the Honorable Tina Brozman Foundation. Dr. Levine has received funding from the National Cancer Institute, the Department of Defense, Stand Up 2 Cancer, and the Gynecologic Oncology Group. He has been awarded the American Congress of Obstetricians and Gynecologists Mentor Award, served as co-chair of the American Association for Cancer Research Special Conferences on Ovarian Cancer, received the 2013 Foundation for Women’s Cancer Excellence in Ovarian Cancer Research Prize, and is the Assistant Dean of the Department of Defense Ovarian Cancer Academy.

For most women with these cancers, surgery is an important part of the initial treatment and increases the possibility of a cure. Many studies have shown that women with gynecologic cancers have better outcomes when their primary surgery is performed by a gynecologic oncologist. In addition to his expertise in the surgical management of gynecologic cancers, he also has special training in minimally invasive surgery (laparoscopy/robotics) and preventive surgery for appropriately selected patients. Intraperitoneal chemotherapy has been proven to be a superior method of treatment for advanced ovarian cancer, and Dr. Levine fully incorporates this into the treatment of appropriate patients. He also performs single-incision laparoscopic surgery (SILS) in appropriate cases, which reduces the number of surgical incisions or scars from four down to only one.

Follow Dr. Levine on Twitter @levinemd.